50 -60岁绝经后骨折女性25(OH)D3和骨密度、骨代谢指标的关系研究

目的探讨50-60岁绝经后骨折女性25羟维生素D_3和骨密度、骨代谢指标的关系。方法选择2014年7月至2015年9月因骨折在我院骨科行手术治疗的50-60岁绝经后女性90例,检测患者腰椎和股骨近端部位骨密度并分为骨质疏松组、骨量减少组及骨量正常组。检测患者身高、体重及25羟维生素D_3、骨碱性磷酸酶、骨钙素、I型胶原羧基末端肽、I型原胶原羧基末端肽及尿Ⅰ型胶原氨基末端肽等骨代谢指标。结果血清25羟维生素D_3水平随着骨密度降低而降低(P0.05);血清骨碱性磷酸酶、骨钙素、I型胶原羧基末端肽、I型原胶原羧基末端肽及尿I型胶原氨基末端肽水平随着血清25羟维生素D_3水平降低而升高(P0.05);血清25羟维生素D_3水平随着年龄增加而降低(P0.05)。结论在50-60岁绝经后女性骨折患者中,血清25羟维生素D_3水平与骨密度存在正性相关关系;血清25羟维生素D_3与血清骨碱性磷酸酶、骨钙素、I型胶原羧基末端肽、I型原胶原羧基末端肽及尿I型胶原氨基末端肽水平存在负性相关关系。50-60岁绝经后女性应及时补充维生素D,并随着绝经年限的增加而适当增加,可以增加骨量,从而可能减少各种并发症的发生。     

维汉老年男性糖尿病患者骨代谢水平分析

目的 探讨汉族和维吾尔族男性糖尿病患者骨代谢水平的特点,为糖尿病性骨质疏松的临床研究提供参数.方法 选择符合研究对象的143名汉族和维吾尔族男性糖尿病患者,测量骨密度(BMD)、骨碱性磷酸酶(BAP)、骨钙素(BGP)、抗酒石酸酸性磷酸酶(TRACP-5b)、25羟基维生素D3(25-(OH) VD3),按BMD值分为...     

骨代谢标志物实验室检测在绝经后骨质疏松症治疗中的意义

目的:探讨骨代谢标志物实验室检测在绝经后骨质疏松症治疗中的意义。方法:选取56例绝经后骨质疏松症患者,给予阿伦膦酸钠,每次70 mg,每周1次,口服。1个疗程为6个月。治疗前后对骨转换标志物甲状旁腺素、骨钙素、I型胶原C端肽、骨性碱性磷酸酶和25羟维生素D3进行检测,分析骨转换标志物的变化。结果:骨钙素和I型胶原C端肽治疗前后比较,差异有统计学意义(P0.05);甲状旁腺素、骨性碱性磷酸酶、25羟维生素D3、血清钙及血清磷治疗前后比较,差异无统计学意义(P0.05)。结论:骨转换标志物骨钙素和I型胶原C端肽可作为判断绝经后骨质疏松症治疗改善的实验室检测指标。     

妊娠糖尿病患者骨代谢标志物水平分析

目的 探讨妊娠糖尿病患者血清N端-骨钙素、总I型胶原氨基端延长肽、β-胶原特殊序列、25-羟基维生素D和甲状旁 腺激素水平的变化。方法 采用病例对照研究,选取妊娠糖尿病患者（GDM组）与同孕周糖耐量正常的孕妇（NGT组）各50 例,测定N端-骨钙素、总I型胶原氨基端延长肽、β-胶原特殊序列、25-羟基维生素D和甲状旁腺激素水平,比较两组人群临床资料和骨代谢标志物水平的差异并进行统计学分析。结果 GDM组孕妇的血清总I型胶原氨基端延长肽为（47. 87 ±34. 84) μg /L,明显高于NGT组的（35.48±10.61)| μg /L (P=0.018),血清β-胶原特殊序列为（0. 226 ±0. 095 ) μg /L ,明显高于NGT组 的（0. 193 ± 0. 054) μg /L（P = 0. 038),血清 N 端-骨钙素为（9. 82 ± 4. 74) μg/L,明显高于 NGT 组的（7. 74 ± 1. 92) μ g/L( P = 0.005。25-羟基维生素D和甲状旁腺激素水平两组间差异无统计学意义。结论 GDM组患者的骨代谢状态主要表现为骨合成代谢和骨吸收代谢均有升高,同时骨转换率也明显升高,尚未发现维生素D和甲状旁腺激素水平与糖耐量正常的孕妇之间有明显差异。     

胶东半岛老年性骨质疏松症骨代谢生化指标 与骨密度相关性研究

目的 研究胶东半岛老年性骨质疏松症(OP)患者骨代谢生化指标与骨密度(BMD)的相关关系,探讨骨代谢生化指标对早期诊断OP的临床意义.方法 采用双能X线骨密度仪(DEXA)对胶东半岛沿海地区多中心多阶段整群抽样297名40～89岁居民进行腰椎(L2-4)BMD测量.采用酶联免疫法(ELISA)分别测定血抗酒石酸酸性磷酸酶(TRAP-5b)、I型胶原C端肽(CTX)、骨特异性碱性磷酸酶 (BALP)、骨钙素(BGP)、降钙素(CT)、25-羟基维生素D[25(OH)D]以及血钙(Ca)和磷(P)并进行比较,应用SPSS13.0软件进行统计分析.结果 OP患者各部位BMD明显低于正常组(均P<0.01).老年男性BMD与骨形成和骨吸收指标呈现降低趋势.其中,OP组较对照组BGP、TRAP-5b和25(OH)D明显下降(P<0.05),而血CTX和BALP较对照组升高.老年女性血TRAP-5b、CTX、BALP和 BGP在OP组显著升高(均P<0.01),而CT和25(OH)D明显降低.各组研究对象骨代谢生化标志物均有统计学意义.结论 骨代谢生物指标作为OP的监测指标,比BMD更加灵敏、特异.能够早期反映患者骨代谢水平,对指导OP的早期预防及治疗有重要意义.     

中药药膳联合八段锦改善寻常型银屑病骨质疏松症状的临床观察

目的观察中药药膳联合八段锦功能锻炼对寻常型银屑病骨质疏松患者的临床疗效。方法将66例患者随机分为两组,对照组(33例)给予中药药膳治疗,试验组(33例)给予中药药膳联合八段锦治疗,采用MYRIAB双能X射线骨密度测量仪,于治疗前后测量腰椎,尺骨远端及桡骨远端骨密度。采用酶联免疫法检测两组患者骨形成指标:骨钙素(BGP),骨特异性碱性磷酸酶(BALP);骨吸收指标:抗酒石酸酸性磷酸酶-5b(TRACP-5b),血清I型胶原交联C端肽(β-CTX),于治疗前及治疗后各检测1次。并采用骨质疏松症状评分表对患者的骨质疏松症状进行评价。6个月后进行比较。结果治疗后,试验组患者骨密度水平明显高于对照组患者,差异具有统计学意义(P0.01);试验组患者骨形成指标血清骨钙素(BGP),骨特异性碱性磷酸酶(BALP)较对照组患者高,差异具有统计学意义(P0.01),骨吸收指标抗酒石酸酸性磷酸酶-5b(TRACP-5b),血清I型胶原交联C端肽(β-CTX)较对照组患者低,差异具有统计学意义(P0.01);临床症状改善方面试验组患者效果明显优于对照组患者,差异具有统计学意义(P0.01)。结论中药药膳联合八段锦功能锻炼可以有效提高寻常型银屑病骨质疏松症患者骨密度,并能有效缓解患者的临床症状。     

胶东半岛健康成年人群骨代谢生化指标与骨密度相关性研究

目的 研究胶东半岛健康成年人群腰椎(L2-L4)骨密度(BMD)与抗酒石酸酸性磷酸酶(TRAP5b)、Ⅰ型胶原C端肽(CTX)、骨特异性碱性磷酸酶(BALP)、骨钙素(BGP)、降钙素(CT)、25-羟基维生素D[25(OH)D]、血清钙(Ca)和磷(P)的相关关系.方法 采用双能X线骨密度仪(DXA)对胶东半岛沿海地区多中心多阶段整群抽样436名21～89岁居民进行BMD测量;采用美国Thermo公司酶标免疫分析仪和HITACHI日立7600-20全自动生化分析仪检测骨代谢指标.将436例受试者按不同性别,每10岁为1个年龄段分组;应用SPSS 13.0分析软件进行统计分析.结果 21～49岁人群TRAP-5b、CTX、BALP、BGP等指标性别间不存在差异;50～89岁人群性别间差异显著,女性高于男性.TRAP-5b、CTX与BMD负相关;女性BALP、BGP在50～69年龄段明显升高,与BMD负相关,70岁以后开始下降.25(OH)D与BMD正相关;CT降低出现在60～89岁年龄段,与BMD显著正相关.血清Ca和P无明显差异.结论 骨代谢指标测定是监测骨量变化及骨质疏松早期诊断的重要技术手段.不同年龄女性骨形成/骨吸收标志物比率不同,绝经后女性骨代谢呈现高转换状态.     

长春市35?79岁人群骨代谢指标与骨密度相关性研究

目的研究抗酒石酸酸性磷酸酶(TRACP)、Ⅰ型胶原C端肽(CTX-1)、骨特异性碱性磷酸酶(BALP)、降钙素(CT)、骨钙素(BGP)、甲状旁腺激素(PTH)、25-羟基维生素D3(25(OH)D3)与前臂远端骨密度相关关系。方法采用美国Osteometer Medi Tech公司生产的DTX-200型骨密度仪检测受试者非受力侧前臂桡、尺骨远端三分之一处骨密度(BMD);采用美国贝克曼公司全自动化学发光免疫分析仪、美国Thermo公司酶标免疫分析仪检测骨代谢指标;将791例受试者检测结果按不同性别,每5岁为一个年龄段分组;应用SPSS13.0分析软件进行统计分析。结果35～49岁人群TRACP、CTX-1、BALP、BGP等指标性别间不存在差异;50～79岁人群性别间差异显著,女性高于男性。TRACP、CTX-1与BMD负相关;女性BALP、BGP在50～64年龄段明显升高,与BMD负相关,65岁以后开始下降。25(OH)D3与BMD正相关;CT降低出现在65～79岁年龄段,与BMD显著正相关。结论骨代谢指标测定是监测骨量变化及骨质疏松早期诊断的重要技术手段。     

铁过载对小鼠血清骨转换指标的影响

目的 观察铁过载小鼠骨质疏松模型中血清骨转换指标的变化.方法 腹腔注射生理盐水和枸橼酸铁铵建立对照和高铁小鼠模型.小动物活体成像系统测定小鼠双侧股骨中段和第四腰椎骨密度.酶联免疫吸附试验(ELISA)检测血清中铁蛋白、骨特异性碱性磷酸酶(BALP)、骨钙素(BGP)、抗酒石酸酸性磷酸酶(TRAP-5b)、Ⅰ型胶原C端肽(CTX)、核因子κB受体活化因子配体(RANKL)、骨保护素(OPG)含量.结果 高铁组小鼠双侧股骨中段和第四腰椎骨密度显著低于对照组(P＜0.05).高铁组小鼠血清中铁蛋白、TRAP-5b、CTX、RANKL含量分别为(269.72±54.06) μg/L、(41.46 ±8.00) U/L、(7720.00 ±3554.00) pmol/L、(94.22±29.79) ng/L,显著高于对照组( 101.18±17.10) μg/L、(19.57±9.02)U/L、(3140.00 ±632.00) pmol/L、(47.70±15.08) ng/L(P＜0.05);BALP、BGP含量分别为(7.84±1.74) μg/L、(58.54±4.60) μg/L,明显低于对照组(18.63±6.23) μg/L、( 100.99±18.22) μg/L(P＜0.05);OPG含量两组之间差异无统计学意义(P＞0.05).结论 铁过载可能通过抑制骨形成,促进骨吸收引起小鼠骨质疏松.     

股骨粗隆间骨折患者手术前后骨代谢、骨密度和骨强度变化研究

目的观察股骨粗隆间骨折患者手术前后骨代谢、骨密度和骨强度的变化,指导术后骨质疏松及骨折的治疗。方法 40例女性股骨粗隆间骨折患者纳入研究,测定入院后次晨及术后3个月的骨代谢指标(Ⅰ型前胶原基端前肽、血清Ⅰ型胶原C端肽、血清骨钙素、甲状旁腺激素、25-羟基维生素D),同时行髋关节骨密度、髋关节骨强度测定,应用SPSS18.0分析软件,对术前及术后3个月上述指标进行统计学分析。结果术后3个月Ⅰ型前胶原基端前肽水平较术前明显升高,血清Ⅰ型胶原C端肽和甲状旁腺激素较术前下降,三者差异具有统计学意义(P0.05);术后3个月,髋关节骨密度、骨强度轻度下降,但与术前比较差异无统计学意义。结论术后3个月,股骨粗隆间骨折患者骨代谢虽然较术前增加,成骨明显,但是骨密度、骨强度无明显改变,仍应加强抗骨质疏松治疗,同时注意防护,避免发生再次骨折。     

The effect of a short course of calcium and vitamin d on bone turnover in older women

Calcium and vitamin D (1200 mg/day + 800 IU) has been shown to reduce hip fracture incidence in older women living in long-term care facilities who had borderline low vitamin D levels. We examined the effect of a short course of calcium and vitamin D on biochemical markers of bone turnover in older community-living women. Twelve community-living women (mean age 75 years) in good general health, without diseases or on medications known to affect bone, were entered into the study. All women were treated with calcium citrate (1500 mg/day of elemental calcium) and vitamin D₃ (1000 IU/day) (Ca + D) for 6 weeks. Biochemical markers of bone turnover were measured in serum and urine collected at baseline (two samples), 5 and 6 weeks on Ca + D, and 5 and 6 weeks after termination of Ca + D. Markers of bone formation were osteocalcin, bone alkaline phosphatase and type I procollagen peptide. Markers of bone resorption were urinary hydroxyproline, free pyridinoline and deoxypyridinoline crosslinks, and N-telopeptides of type I collagen. Parathyroid hormone (PTH) and 25-hydroxyvitamin D were also measured at baseline, 6 weeks on treatment and 6 weeks after termination of treatment. All markers of bone resorption decreased on Ca + D and returned to baseline after termination of Ca + D (p<0.05). Markers of bone formation did not change with Ca + D treatment. PTH decreased on Ca + D and returned to baseline after treatment, and 25-hydroxyvitamin D increased with treatment and remained elevated 6 weeks after the end of treatment. We conclude that Ca + D reduces bone resorption in older women, possibly by suppressing PTH levels.     

High prevalence of hypovitaminosis D in pregnant Japanese women with threatened premature delivery

Serum 25-hydroxyvitamin D (25-OHD) concentrations are thought to accurately reflect vitamin D stores, and vitamin D deficiency causes secondary hyperparathyroidism, irreversible bone loss, and increased risk of fracture. Recent studies suggest that decrease of serum 25-OHD level in mothers could increase the risk of preeclampsia, cesarean section, and craniotabes. Furthermore, this deficiency may affect bone mass and the incidence of neuromuscular diseases of their children in the future. In the present study, the serum concentration of 25-OHD in 93 pregnant women after the 30th week of their gestation was determined by direct radioimmunoassay. Mean 25-OHD levels in spring, summer, fall, and winter were 14.3 ± 5.1, 15.7 ± 6.4, 13.7 ± 5.1, and 13.9 ± 4.2 ng/ml, respectively. Severe vitamin D deficiency (25-OHD < 10 ng/ml) was found in 10 of these 93 women. Overall, hypovitaminosis D, which was defined as serum 25-OHD concentration equal to or less than 20 ng/ml, was revealed in 85 mothers (89.5%). Serum 25-OHD levels were not associated with either intact parathyroid hormone or corrected calcium concentrations, but were negatively associated with serum type I collagen N-terminal telopeptide and bone-specific alkaline phosphatase in these subjects. Mothers with threatened premature delivery had significantly lower 25-OHD levels (11.2 ± 3.2 ng/ml) than those in mothers with normal delivery (15.6 ± 5.1 ng/ml). In conclusion, the present data suggest a high prevalence of hypovitaminosis D in perinatal pregnant Japanese women throughout the year, which seems to affect bone metabolism and to be associated with threatened premature delivery.     

Serum levels of 25-hydroxyvitamin D in postmenopausal osteoporosis

Summary Serum concentrations of 25-hydroxyvitamin D were measured in a group of women with symptomatic postmenopausal osteoporosis, assessed by bone biopsy. A competitive protein binding assay was used, which included a chromatographic step. Accurate surveys of dietary or therapeutic vitamin D intake and light environment were obtained in each patient. Women with severe postmenopausal osteoporosis were found to have significantly (P<0.001) higher serum levels of 25-hydroxyvitamin D than age-matched normal women, the mean values being 27.5 ng/ml (±13.6 SD) and 8.2 ng/ml (±5.7), respectively. The authors hypothesize that the reduction in 1,25-dihydroxyvitamin D, recently reported in postmenopausal osteoporotic women, might be responsible for the increased serum levels of 25-hydroxyvitamin D through an inadequate product inhibition of liver vitamin D 25-hydroxylase.     

Comparison of biochemical markers of bone metabolism in serum and femur aspirates

In 27 patients undergoing arthroscopy of the knee for treatment of meniscal diseases, biochemical markers of bone metabolism were measured in cancellous bone, and levels were compared with concentrations obtained from peripheral blood. Bone-specific alkaline phosphatase, osteocalcin, and collagen Type I metabolites (procollagen Type I N-terminal peptide and carboxy-terminal cross-linked telopeptide) were studied simultaneously in serum and in the distal femur using a radioimmunoassay. Although levels of bone-specific alkaline phosphatase and osteocalcin did not differ between serum and cancellous bone, concentrations of collagen Type I metabolites were elevated significantly in healthy cancellous bone. The close correlations between bone and serum concentrations confirmed accuracy of results obtained from cancellous bone. The mean bone-to-serum ratio for alkaline phosphatase and osteocalcin was 1.1 and 1.2, respectively. Collagen Type I metabolite ratios of 2.2 (for carboxy-terminal cross-linked telopeptide) and 2.3 (for procollagen Type I N-terminal peptide) indicate that these markers are formed locally and then released into the circulation. Bone seems to be a major contributor of collagen Type I metabolites to the serum pool.     

Osteoporosis and Bone Mineral Metabolism Disorders in Cirrhotic Patients Referred for Orthotopic Liver Transplantation

The purpose of this study was to determine the prevalence of osteoporosis, to estimate the bone turnover and hormonal status, and to identify the factors associated with bone disease in patients with end-stage liver disease who were referred for orthotopic liver transplantation. A prospective study was performed on 58 cirrhotic patients (6 with primary biliary cirrhosis, 14 with alcoholic cirrhosis, and 38 with posthepatitic cirrhosis), who were referred for orthotopic liver transplantation. Patients, excluding those with primary biliary cirrhosis, were classified in Child-Pugh groups according to the severity of liver disease (class B [28 patients], class C [24 patients]). Biochemical parameters of bone mineral metabolism and standard liver function tests were measured in all patients. Additionally, serum osteocalcin, urinary hydroxyproline/creatinine ratio, serum intact parathyroid hormone, serum 25-hydroxyvitamin D, serum 1,25-dihydroxyvitamin D, folliclestimulating hormone, and luteinizing hormone levels were determined in patients and controls within the same age range. Plasma testosterone, sex hormone-binding globulin levels, and free testosterone index were obtained for all men included in the study. Bone mass of the lumbar spine and femur were measured by dual X-ray absorptiometry (DPX-L), and were expressed as a standard deviation of mean values (Z-score) from a sex and age-matched control group. Spinal X-rays were obtained to assess vertebral fractures. Osteoporosis was considered as a factor in spinal bone mineral density with a Z-score below 2 or at least one vertebral fracture. Twenty-five patients (43%) had osteoporosis, with lower bone mass measurements in the lumbar spine than in the femoral neck (P < 0.005). Alcoholic and Child-Pugh C patients showed the lowest femoral bone mineral density values. Cirrhotic patients showed lower osteocalcin levels than controls (14.3 ± 5.9 vs. 18.2 ± 8.1 ng/ml; P < 0.05) and showed increased urinary hydroxyproline (125.1 ± 51.5 vs. 107.9 ± 26.6 nM/mg creatinine; P < 0.05). Serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone levels were significantly lower in cirrhotic patients than in controls (10.3 ± 9.1 vs. 23.1 ± 26.6 ng/ml; P= 0.000), (12.9 ± 9.1 vs. 48.3 ± 11.5 pg/ml; P= 0.000), (16.6 ± 9.2 vs. 27.9 ± 8.2 pg/ml; P= 0.000), with no differences between Child-Pugh groups. Alcoholic Child-Pugh C patients showed the lowest 25-hydroxyvitamin D serum values (4.5 ± 2.2 ng/ml; P < 0.05). Male patients had lower testosterone levels than controls (302.5 ± 229.4 vs. 556.7 ± 146.5 ng/dl; P= 0.000), with increased sex hormone-binding globulin values. Levels of testosterone and gonadotropin were related to Child-Pugh classification. No correlation was found between bone mass and hormonal values. A significant decrease in bone mass, particularly in the lumbar spine, is seen in end-stage cirrhotic patients. Reduced bone formation and significant disorders of bone mineral metabolism, such as vitamin D deficiency, reduced parathyroid hormone levels, and hypogonadism are involved. Moreover, severity and etiology of the liver disease are the main risk factors for developing bone loss and mineral metabolism disorders in patients referred for orthotopic liver transplantation. Received: 7 March 1996 / Accepted: 24 June 1996     

Alteration in osteoblast activity and nutritional vitamin-D deficiency in non-hypercalcemic malignancy

Summary The biochemical parameters of bone mineral metabolism in patients with nonhypercalcemic malignancy have not been extensively investigated. Therefore, a group of 29 such patients with different types of malignancy was studied. Ten patients received corticosteroids. In the entire group, serum ionized calcium (Ca²⁺), bone gla protein (BGP), 25-hydroxyvitamin D (25OHD), and 1,25-dihydroxyvitamin D (1,25(OH)₂D) were all lower than in age-matched controls, and carboxy-terminal parathyroid hormone (CPTH) was higher. Although both corticosteroid- and noncorticosteroid-treated patients had decreased BGP values, the corticosteroid-treated patients had lower BGP levels than those not on steroids (4.24±0.70 SE vs. 11.50±2.20 ng/ml;P<0.005). Patients on corticosteroids had lower 1,25(OH)₂D values than controls (18.81 ±2.71 vs. 27.83±1.17 pg/ml;P<0.01), whereas those not on corticosteroids had normal 1,25(OH)₂D values. These results suggest that patients with nonhydpercalcemic malignancy have nutritional vitamin-D deficiency and secondary hyperparathyroidism with perhaps corticosteroid-induced suppression of serum 1,25(OH)₂D and BGP. The decreased levels of serum BGP in the nonsteroid-treated patients suggest, in addition, a defect in osteoblast function.     

Vitamin D: A Necessity for Children and Adolescents in Greece

Children and adolescents with the high bone turnover comprise a high risk population for vitamin D insufficiency. A sample of 178 clinically healthy children aged 3 to 18 years who came from public schools and lived in North West of Greece participated in the study. They were grouped into three age groups (I: 3–10, II: 11–14 and III: 15–18 years of age). Blood samples were taken during winter and summer months for determining calciotropic hormones, calcium, phosphate and biochemical markers of bone synthesis. A high percentage (47%) of the subjects aged 15–18 years was found to have 25OHD <10 ng/ml in winter but much less (13–14%) of the younger ages (13–14 years), while in the summer they were all >10 ng/ml. The prevalence was even higher in the girls of the older group accompanied by lower Pi concentrations again in winter (win:1.19±0.03, sum:1.93±0.03 mmol/l, p < 0.001). The 24,25(OH)₂D levels were changing in parallel to 25OHD, but again in the older subjects, during winter, they were by 2/3 lower than the summer ones (0.73±0.10 vs. 2.41±0.20 ng/ml, p < 0.001). No significant differences were found between seasons and groups in the 1,25(OH)₂D levels. The biochemical markers of bone synthesis, osteocalcin (OC) and total alkaline phosphatase (ALP), were found significantly lower in the girls of the older group both in winter and summer respectively.Even in a sunny country like Greece the adolescents living in an urban area are in high risk for vitamin D deficiency during winter. Supplementation with vitamin D of milk, of popular beverages and perhaps some foods would be of help.     

Vitamin K status in relation to bone metabolism in patients with renal failure

Vitamin K abnormalities may be involved in the pathogenesis of bone disease in patients with advanced renal failure since vitamin K plays a role in the synthesis of osteocalcin, a marker of bone formation. Vitamin K may also indirectly suppress parathyroid function. The aim of this study was to evaluate vitamin K status in patients with renal failure and in healthy volunteers in relation to some biochemical markers of bone turnover. The studies were performed on: patients with chronic renal failure (CRF) on conservative treatment; hemodialyzed patients treated with continuous ambulatory peritoneal dialysis (CAPD); kidney transplant patients, and a control group. Intact PTH, osteocalcin, vitamin 1,25-(OH)(2)D(3), 25-OH-D(3), bone-specific alkaline phosphatase, procollagen type-I cross-linked carboxyterminal telopeptide, deoxypyridinoline, and osteonectin were assayed using commercially available kits, and the vitamin K concentration by HPLC. We found that vitamin K concentrations did not differ significantly between all the groups studied. Only in CRF patients was the vitamin K concentation low, almost reaching statistical significance when compared to the healthy volunteers (p = 0.05) and correlated positively with age, serum calcium and osteonectin. No statistically significant correlations were found between vitamin K and osteocalcin, PTH or other biochemical parameters of bone metabolism studied in patients with CRF and renal replacement therapy. In patients after renal replacement therapy, the only significant positive correlation was found between phylloquinone and osteonectin (r = 0.027, p = 0.004). The same applied when we also included healthy volunteers. The correlations of osteonectin and vitamin K are of unknown clinical relevance. Our study does not support the hypotheses of a possible role of vitamin K deficiency in patients with CRF and the influence of vitamin K on bone metabolism.     

血清25-羟维生素D浓度检测对膝骨关节炎临床诊疗意义

目的：研究与探讨血清25－羟基维生素D浓度检测对膝骨关节炎临床诊疗的指导意义。方法随机抽取2011年6月至2011年10月以及2012年6月至2012年10月期间骨科门诊主诉有膝关节疼痛患者1174名,采用罗氏诊断试剂盒检测患者血清中的25－羟基维生素D浓度。结果1174例患者平均年龄（53．61±15．10）岁,血清25－羟维生素D浓度平均值为15．55 ng／ml,维生素D缺乏者（＜20 ng／ml）占48．12％（524例）,其中严重缺乏者（＜10 ng／ml）占26．35％（287例）。2011年测得血清25－羟基维生素D浓度平均值为13．27 ng／ml（参考值为11．10～42．90 ng／ml）;2012年测得血清25－羟基维生素D浓度平均值为22．53 ng／ml（参考值为20～32 ng／ml）。结论血清25－羟基维生素D浓度检测在膝骨关节炎诊疗中具有重要指导意义。本次研究中应用的罗氏诊断血清25－羟维生素D3检测试剂参考值有波动,直接导致2011年度与2012年度同期所检测出的患者血清25－羟基维生素D浓度存在一定的偏差。     

Procollagen type I C-terminal extension peptide in predialysis chronic renal failure.

Collagen type 1 is the most abundant protein of bone. Serum levels of type 1 procollagen carboxy-terminal extension peptide (Procoll-1-C) may give a measure of the rate of synthesis of the collagen of bone and be therefore a marker of bone turnover. We have studied 38 patients with predialysis chronic renal failure; 14 of them were under long-term treatment with 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] for prevention of secondary hyperparathyroidism. In all patients a transiliac bone biopsy for histomorphometry and determination of dynamic parameters was performed following double tetracycline labeling. In addition serum Procoll-1-C, intact and C-terminal parathyroid hormone (PTH), osteocalcin and alkaline phosphatase were determined. In the patients not receiving 1,25(OH)2D3, serum levels of Procoll-1-C were higher than normal. Procoll-1-C did not correlate with any of the humoral parameters, including serum creatinine, nor with static histomorphometric parameters. Contrarily to osteocalcin, the collagen type 1 marker correlated significantly with all dynamic parameters. Treatment with 1,25(OH)2D3 was accompanied by lower levels of osteocalcin, iPTH (n.s.), osteoblastic surface and by normal levels of Procoll-1-C (p < 0.001, compared to untreated patients), without substantial change in bone formation parameters (bone formation rate). In conclusion Procoll-1-C in predialysis chronic renal failure is a marker of bone turnover unparalleled by other markers. 1,25(OH)2D3 administration is associated with lower serum levels of the peptide unaccompanied by a decrement of bone formation parameters, therefore with an apparently better utilization of collagen type 1 in the mineralization process.(ABSTRACT TRUNCATED AT 250 WORDS)